Eurican Herpes 205

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Antiġeni tal-herpesvirus tal-klieb (strain F205)

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QI07AA

INN (International Name):

Canine herpes vaccine (inactivated subunit)

Therapeutic group:

Klieb

Therapeutic area:

Immunoloġiċi għall-canidae

Therapeutic indications:

Immunizzazzjoni attiva ta 'klieb nisa biex jipprevjenu l-mortalità, sinjali kliniċi u leżjonijiet fi ġriewi li jirriżultaw minn infezzjonijiet tal-virus tal-herpes tal-klieb akkwistati fl-ewwel ftit jiem tal-ħajja.

Product summary:

Revision: 12

Authorization status:

Awtorizzat

Authorization date:

2001-03-26

Patient Information leaflet

                                14
B. FULJETT TA’ TAGĦRIF FIL-PAKKETT
15
FULJETT TA’ TAGĦRIF FIL-PAKKETT:
EURICAN HERPES 205 TRAB U SOLVENT GĦAL EMULSJONI GĦALL-INJEZZJONI
1.
L-ISEM U L-INDIRIZZ TAS-SID TAL-AWTORIZZAZZJONI TAL-KUMMERĊ, U L-
ISEM U L-INDIRIZZ TAS-SID TAL-AWTORIZZAZZJONI TAL-MANIFATTURA
RESPONSABBLI LI JĦALLI L-KONSENJA TMUR FIS-SUQ , JEKK DIFFERENTI
Sid l-Awtorizzazzjoni tal-Kummerċ :
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
IL-ĠERMANJA
Manifattur li jħalli l-konsenja tmur fis-suq:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l’Aviation
69800 Saint Priest
Franza
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Eurican Herpes 205 trab u solvent għal emulsjoni għall-injezzjoni
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
Għal kull doża ta’ ml
Lijofiliżat
SUSTANZA ATTIVA
Antiġeni tal-herpesvirus fil-klieb (F205 strain)
0.3 sa 1.75 µg*
*espressi f’µg ta’ glicoproteini gB
Solvent:
AĠĠUVANT
Żejt paraffin ħafif
224.8 sa’ 244.1 mg
Lijofiliżat : Pritkuna bajda
Solvent: emulsjoni bajda omoġena
4.
INDIKAZZJONI (JIET)
Immunizzazzjoni attiva ta’ klieb nisa tqal biex tipprevjeni
l-mortalità, sinjali kliniċi u leżjonijiet fil-
ġriewi kkaġunati mill-infezzjonijiet tal-herpesvirus fil-klieb
miksuba fl-ewwel ftit ġranet tal-ħajja.
5.
KONTRAINDIKAZZJONIJIET
Xejn.
16
6.
EFFETTI MHUX MIXTIEQA
Il-vaċċin jista’ komunament jikkawża edema li tgħaddi fil-post
tal-injezzjoni. Dawn ir-reazzjonijiet
is-soltu jinżlu fi żmien ġimgħa.
Rarament jista’ jkun hemm reazzjonijiet ta’ ipersensittività.
Kura xierqa sintomatika għanda tiġi
amministrata.
Il-frekwenza ta’ effetti mhux mixtieqa hija definita skont din
il-konvenzjoni:
-
komuni ħafna (aktar minn wieħed f’10 annimali kkurati li juru
effett(i) mhux mixtieq(a))
-
komuni (aktar minn wieħed iżda inqas minn 10 annimali f’100
annimal ikkurat)
-
mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f’1,000
annimal ikkurat)
-
rari (aktar minn wieħed iżda inqas minn10 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
Eurican Herpes 205 trab u solvent għal emulsjoni għal injezzjoni.
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Għal kull doża ta’ ml:
Lijofiliżat:
SUSTANZA ATTIVA :
Antiġeni tal-herpesvirus fil-klieb (F205 strain)
.......................... 0.3 sa 1.75 µg*
*espressi f’µg ta’ glicoproteini ta’ gB
Solvent
:
AĠĠUVANT :
Żejt paraffin ħafif
........................................................................................................
224.8 sa 244.1 mg
Sustanzi mhux attivi:
Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni
6.1.Sustanzi mhux attivi:
3.
GĦAMLA FARMAĊEWTIKA
Trab u solvent għal emulsjoni għal injezzjoni.
Lijofiliżat : Pritkuna bajda
Solvent: emulsjoni bajda omoġena
4.
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Immunizzazzjoni attiva ta’ klieb nisa tqal biex tipprevjeni
l-mortalità, sinjali kliniċi u leżjonijiet fil-
ġriewi kkaġunati mill-infezzjonijiet tal-herpesvirus fil-klieb
miksuba fl-ewwel ftit ġranet tal-ħajja
permezz ta’ immunità passiva.
4.3
KONTRAINDIKAZZJONIJIET
Xejn
4.4
TWISSIJIET SPEĊJALI GĦAL KULL SPEĊI LI GĦALIHA HU INDIKAT
IL-PRODOTT
Laqqam biss annimali f’saħħithom.
L-infezzjoni CHV fil-klieb nisa tista’ tikkawża abort jew twelid
prematur bħala riżultat, il-protezzjoni
tal-kelba kontra l-infezzjoni ma ġietx studjata għal dan
il-vaċċin. Sabiex limmunità tiġi mgħotija lill-
ġriewi, ammont suffiċjenti ta’ kolostrum huwa meħtieġ.
4.5
PREKAWZJONIJIET SPEĊJALI GĦALL-UŻU
Prekawzjonijiet speċjali għall-użu fl-annimali
Xejn.
3
Prekawzjonijiet speċjali li għandhom jittieħdu mill-persuna li
tamministra l-prodott mediċinali
veterinarju lill-annimali
Għal min se juża:
Dan il-prodott veterinarju mediċinali fih żejt minerali. Injezzjoni
aċċidentali jew jekk tinjetta lilek
innifsek
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 20-08-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 20-08-2020
Public Assessment Report Public Assessment Report Bulgarian 16-02-2021
Patient Information leaflet Patient Information leaflet Spanish 20-08-2020
Public Assessment Report Public Assessment Report Spanish 16-02-2021
Patient Information leaflet Patient Information leaflet Czech 20-08-2020
Public Assessment Report Public Assessment Report Czech 16-02-2021
Patient Information leaflet Patient Information leaflet Danish 20-08-2020
Public Assessment Report Public Assessment Report Danish 16-02-2021
Patient Information leaflet Patient Information leaflet German 20-08-2020
Public Assessment Report Public Assessment Report German 16-02-2021
Patient Information leaflet Patient Information leaflet Estonian 20-08-2020
Public Assessment Report Public Assessment Report Estonian 16-02-2021
Patient Information leaflet Patient Information leaflet Greek 20-08-2020
Public Assessment Report Public Assessment Report Greek 16-02-2021
Patient Information leaflet Patient Information leaflet English 20-08-2020
Public Assessment Report Public Assessment Report English 16-02-2021
Patient Information leaflet Patient Information leaflet French 20-08-2020
Public Assessment Report Public Assessment Report French 16-02-2021
Patient Information leaflet Patient Information leaflet Italian 20-08-2020
Public Assessment Report Public Assessment Report Italian 16-02-2021
Patient Information leaflet Patient Information leaflet Latvian 20-08-2020
Public Assessment Report Public Assessment Report Latvian 16-02-2021
Patient Information leaflet Patient Information leaflet Lithuanian 20-08-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 20-08-2020
Public Assessment Report Public Assessment Report Lithuanian 16-02-2021
Patient Information leaflet Patient Information leaflet Hungarian 20-08-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 20-08-2020
Public Assessment Report Public Assessment Report Hungarian 16-02-2021
Patient Information leaflet Patient Information leaflet Dutch 20-08-2020
Public Assessment Report Public Assessment Report Dutch 16-02-2021
Patient Information leaflet Patient Information leaflet Polish 20-08-2020
Public Assessment Report Public Assessment Report Polish 16-02-2021
Patient Information leaflet Patient Information leaflet Portuguese 20-08-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 20-08-2020
Public Assessment Report Public Assessment Report Portuguese 16-02-2021
Patient Information leaflet Patient Information leaflet Romanian 20-08-2020
Public Assessment Report Public Assessment Report Romanian 16-02-2021
Patient Information leaflet Patient Information leaflet Slovak 20-08-2020
Public Assessment Report Public Assessment Report Slovak 16-02-2021
Patient Information leaflet Patient Information leaflet Slovenian 20-08-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 20-08-2020
Public Assessment Report Public Assessment Report Slovenian 16-02-2021
Patient Information leaflet Patient Information leaflet Finnish 20-08-2020
Public Assessment Report Public Assessment Report Finnish 16-02-2021
Patient Information leaflet Patient Information leaflet Swedish 20-08-2020
Public Assessment Report Public Assessment Report Swedish 16-02-2021
Patient Information leaflet Patient Information leaflet Norwegian 20-08-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 20-08-2020
Patient Information leaflet Patient Information leaflet Icelandic 20-08-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 20-08-2020
Patient Information leaflet Patient Information leaflet Croatian 20-08-2020